Isofol Medical AB’s (publ) Board of Directors has resolved on a fully guaranteed new share issue with preferential rights for Isofol’s existing shareholders. Through the transaction, the company will receive approximately SEK 150 million before transaction costs.

In addition to the rights offering, the Board of Directors is authorized to carry out a directed share issue with deviation from the shareholders’ preferential rights of up to approximately SEK 30 million. Any such directed share issue is conditional upon the rights offering being oversubscribed.

Isofol is a clinical stage biotech company developing arfolitixorin to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer by increasing tumor response and progression free survival.

The purpose of the rights offering and the potential directed share issue is to ensure the continued and successful development of the company, in accordance with its business plan and strategy.

Carnegie Investment Bank AB (publ) and Pareto Securities AB are Joint Bookrunners in connection with the transactions. Baker McKenzie acts as legal adviser to the Joint Bookrunners with a team consisting of Joakim Falkner, Johanna Flink and Ian Gulam.
Explore Our Newsroom